Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study

[1]  C. Geyer,et al.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Allen,et al.  Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study , 2012, Journal of the National Cancer Institute.

[3]  D. Sawyer,et al.  Cardiac Side Effects of Anticancer Treatments: New Mechanistic Insights , 2012, Current Heart Failure Reports.

[4]  J. Baselga,et al.  Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  L. Tarantini,et al.  Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. , 2012, Journal of cardiac failure.

[6]  Juxiang Chen,et al.  Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. , 2011, Cancer treatment reviews.

[7]  R. Gelber,et al.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.

[8]  Giuseppe Curigliano,et al.  Cardiac toxicity from systemic cancer therapy: a comprehensive review. , 2010, Progress in cardiovascular diseases.

[9]  J. Zamorano,et al.  Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. , 2008, Mayo Clinic proceedings.

[10]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[11]  J. Robins,et al.  Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. , 2006, American journal of epidemiology.

[12]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Gage,et al.  Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.

[14]  D. Keefe,et al.  Trastuzumab‐associated cardiotoxicity , 2002, Cancer.

[15]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[16]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[17]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[18]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[19]  M. Zibelman,et al.  Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer , 2013 .

[20]  M. Dowsett,et al.  years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial , 2013 .

[21]  D. Sawyer,et al.  ERBB2 inhibition and heart failure. , 2013, The New England journal of medicine.